Radiotherapy and surgery provide regional control for breast cancer patients
Both axillary lymph node dissection and axillary radiotherapy provide excellent regional control for breast cancer patients with a positive sentinel node biopsy, according to a final study analysis. Also, axillary radiotherapy reduces the risk of short-term and long-term lymphoedema as compared to axillary lymph node dissection.
This final analysis of the AMAROS (After Mapping of the Axilla: Radiotherapy or Surgery?) trial, conducted by the European Organisation for the Research and Treatment of Cancer (EORTC), was led by Professor Emiel J. Rutgers, MD, of The Netherlands Cancer Institute-Antoni Van Leeuwenhoek Ziekenhuis in Amsterdam and of the EORTC Breast Cancer Group. He said, "Sentinel node biopsy has become the standard procedure for assessing axillary lymph node status for cN0 breast cancer patients. At the start of this trial the question was whether axillary lymph node dissection should remain the standard treatment in case of a tumor positive sentinel node."
From 2001 to 2010, 4806 patients who were diagnosed with invasive breast cancer were enrolled in this phase III noninferiority trial, and randomized for their axillary treatment when their sentinel node biopsies were positive. Of these, 3131 patients had negative biopsies and 25[WU1] patients had a different sentinel node outcome. Thus, out of 1425 node-positive patients, axillary lymph node dissection was used in 744 patients, and axillary radiotherapy in 681 patients.
"Although axillary lymph node dissection provides excellent regional control, it was known to cause harmful side effects. Axillary radiotherapy instead of axillary lymph node dissection was hypothesized to provide comparable regional control and perhaps fewer side effects in this particular group of patients," said Geertjan van Tienhoven, MD, PhD, of the Academisch Medisch Centrum - Universiteit van Amsterdam and principal investigator on behalf of the EORTC Radiation Oncology Group.
The primary end point of this EORTC trial was 5-year axillary recurrence rate. At a median follow-up of 6.1 years, this rate was 0.54% (4 out of 744 patients) after axillary lymph node dissection and 1.03% (7 out of 681 patients) after axillary radiotherapy. Due to the unexpectedly low number of events, the non-inferiority test was underpowered. The axillary recurrence rate for patients with a negative sentinel node biopsy was 0.8% (25 out of 3131 patients).
Secondary end points were overall survival, disease-free survival, quality of life, shoulder movement, and lymphoedema at one and five years. No significant differences in overall or disease-free survival were observed between the two treatment arms. Five year estimates for overall survival were 93.3% for the arm receiving axillary lymph node dissection and 92.5% for patients in the axillary radiotherapy arm (P=0.34). For disease-free survival, the five year estimates were 86.9% for axillary lymph node dissection and 82.6% for axillary radiotherapy (P=0.18).Lymphoedema, a swelling of tissue (typically occurring in the arm), occurred more often following axillary lymph node dissection, 40% at one year and 28% at five years, than after axillary radiotherapy, 22% at one year and 14% at five years (P<0.0001).